Summary & Overview
HCPCS A9538: Technetium tc-99m Pyrophosphate Diagnostic Per-Study Dose
HCPCS Level II code A9538 denotes technetium tc-99m pyrophosphate used for diagnostic nuclear medicine studies, billed per study dose up to 25 millicuries. This radiopharmaceutical is used in imaging protocols where localization of tracer uptake provides clinical information, and accurate coding supports appropriate facility billing and clinical documentation. Nationally, proper use of A9538 matters for standardized reporting of nuclear medicine procedures and for aligning reimbursements with radiopharmaceutical costs and facility resource utilization.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find concise benchmarks on payer coverage patterns, common billing practices, and the clinical context in which A9538 is used. The publication outlines payer-specific considerations, relevant coding practices for radiopharmaceutical billing, and typical sites of service where this code is applied. It also highlights gaps where input data was not provided, such as associated taxonomies, ICD-10 diagnoses, and related codes, which are noted as "Data not available in the input." Overall, the summary provides stakeholders with a national view of coding for technetium tc-99m pyrophosphate diagnostic studies and what to expect when billing under A9538.
Billing Code Overview
HCPCS Level II code A9538 represents Technetium tc-99m pyrophosphate administered for diagnostic imaging, billed per study dose, up to 25 millicuries. This service involves intravenous delivery of the radiopharmaceutical to visualize physiologic or pathologic processes using nuclear medicine imaging techniques.
-
Service type: Diagnostic nuclear medicine radiopharmaceutical administration
-
Typical site of service: Outpatient imaging centers, hospital nuclear medicine departments, and other licensed facilities providing diagnostic nuclear medicine studies
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult referred to nuclear medicine for evaluation of suspected myocardial infarction, cardiac amyloidosis, or myocardial necrosis where technetium pyrophosphate imaging is indicated. The patient arrives to an outpatient imaging center or hospital radiology/nuclear medicine department after clinical assessment in the emergency department, cardiology clinic, or inpatient ward. The nuclear medicine technologist confirms identity, checks for contraindications (recent radiopharmaceutical studies that may interfere, pregnancy, or breastfeeding), obtains informed consent as required by facility policy, and documents medication and allergy history. The technologist administers A9538 (Technetium tc-99m pyrophosphate) intravenous dose up to 25 millicuries. Imaging acquisition is performed by a nuclear medicine technologist or radiologic technologist under the supervision of a nuclear medicine physician or cardiologist, using planar and/or SPECT cardiac imaging protocols appropriate to the indication. The interpreting physician reviews images, correlates with clinical data (ECG, troponin levels, echocardiography), and provides a diagnostic report. The radiopharmaceutical dose billing uses A9538 for the per-study dose; technical and professional components of imaging may be billed separately using CPT procedures and applicable modifiers.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 |